Skip to main content

Glimpse Group, Inc.

For the period ended Jun 30, 2025. Filed Sep 29, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Sep 29, 2025

BTLN$3.67+4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED JUNE 30, 2025 and 2024

Common Stock · Additional · Accumulated
SharesAmountPaid-In CapitalDeficitTotal
Balance as of July 1, 202314,701,929$14,702$67,854,108$(56,644,978)$11,223,832
Common stock and stock option based compensation expense399,2013992,009,402-2,009,801
Common stock issued to vendors44,19744100,328-100,372
Stock option-based board of directors expense332,642333655,295-655,628
Common stock issued for exercise of options8,8199(9)--
Common stock issued in Securities Purchase Agreement, net1,885,7151,8862,966,615-2,968,501
Common stock issued to satisfy contingent acquisition obligations785,714785973,861-974,646
Net loss---(6,394,295)(6,394,295)
Balance as of June 30, 202418,158,217$18,158$74,559,600$(63,039,273)$11,538,485
Common stock and stock option based compensation expense37,00037754,717-754,754
Common stock issued to vendors2,50034,598-4,601
Stock option-based board of directors expense--229,389-229,389
Common stock issued for exercise of options7,7898(8)--
Common stock issued in Securities Purchase Agreement, net1,990,0001,9906,783,562-6,785,552
Common stock issued for exercise of warrants860,000860174,900-175,760
Net loss---(2,552,651)(2,552,651)
Balance as of June 30, 202521,055,506$21,056$82,506,758$(65,591,924)$16,935,890
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.